Citation Tools
PDFRegular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models